Mundipharma pays Allos $50 million up front for ex-US rights to lymphoma drug
This article was originally published in Scrip
Executive Summary
Allos Therapeutics has achieved its goal of securing a strategic ex-US partner for its peripheral T-cell lymphoma (PTCL) drug Folotyn (pralatrexate), signing a deal granting Mundipharma International certain rights to co-develop and commercialise the product.